Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;230(2):291-8.
doi: 10.1007/s00213-013-3153-2. Epub 2013 Jun 4.

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

Luli Akinfiresoye  1 , Yousef Tizabi
Affiliations

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

Luli Akinfiresoye et al. Psychopharmacology (Berl). 2013 Nov.

Abstract

Rationale: A number of preclinical and clinical studies suggest that ketamine, a glutamate N-methyl-D-aspartate receptor antagonist, has a rapid and lasting antidepressant effect when administered either acutely or chronically. It has been postulated that this effect is due to stimulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.

Objective: In this study, we tested whether AMPA alone has an antidepressant effect and if the combination of AMPA and ketamine provides added benefit in Wistar-Kyoto rats, a putative animal model of depression.

Results: Chronic AMPA treatment resulted in a dose-dependent antidepressant effect in both the forced swim test and sucrose preference test. Moreover, chronic administration (10-11 days) of combinations of AMPA and ketamine, at doses that were ineffective on their own, resulted in a significant antidepressant effect. The behavioral effects were associated with increases in hippocampal brain-derived neurotrophic factor, synapsin, and mammalian target of rapamycin.

Conclusion: These findings are the first to provide evidence for an antidepressant effect of AMPA and suggest the usefulness of AMPA-ketamine combination in treatment of depression. Furthermore, these effects appear to be associated with increases in markers of hippocampal neurogenesis and synaptogenesis, suggesting a mechanism of their action.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflict of interest

Figures

Fig 1
Fig 1
Effects of various doses of AMPA on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
Fig 1
Fig 1
Effects of various doses of AMPA on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
Fig 1
Fig 1
Effects of various doses of AMPA on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
Fig 2
Fig 2
Effect of low doses of AMPA (0.25 mg/kg or 0.5 mg/kg), ketamine (0.25 mg/kg or 0.5 mg/kg), and their combination on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8
Fig 2
Fig 2
Effect of low doses of AMPA (0.25 mg/kg or 0.5 mg/kg), ketamine (0.25 mg/kg or 0.5 mg/kg), and their combination on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8
Fig 2
Fig 2
Effect of low doses of AMPA (0.25 mg/kg or 0.5 mg/kg), ketamine (0.25 mg/kg or 0.5 mg/kg), and their combination on (a) FST immobility, (b) FST swimming, (c) sucrose preference, and (d) locomotor activity in WKY rats. Animals were treated once daily for 11 consecutive days. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8
Fig 3
Fig 3
Effect of very low doses of AMPA (0.25 mg/kg), ketamine (0.25 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin) and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, **p<0.01 compared to SAL, n=7–8.
Fig 3
Fig 3
Effect of very low doses of AMPA (0.25 mg/kg), ketamine (0.25 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin) and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, **p<0.01 compared to SAL, n=7–8.
Fig 3
Fig 3
Effect of very low doses of AMPA (0.25 mg/kg), ketamine (0.25 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin) and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, **p<0.01 compared to SAL, n=7–8.
Fig 4
Fig 4
Effect of low doses of AMPA (0.5 mg/kg), ketamine (0.5 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin), and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
Fig 4
Fig 4
Effect of low doses of AMPA (0.5 mg/kg), ketamine (0.5 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin), and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
Fig 4
Fig 4
Effect of low doses of AMPA (0.5 mg/kg), ketamine (0.5 mg/kg), and their combination on markers of neurogenesis (BDNF), synaptogenesis (synapsin), and the signal transduction protein (mTOR) in the hippocampus. (a) Immunoblots, (b) BDNF, (c) synapsin, (d) mTOR. Values are mean ± SEM, *p<0.05 **p<0.01 compared to SAL, n=7–8.
See this image and copyright information in PMC

References

    1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–145. - PubMed
    1. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem. Pharmacology. 2006;71:1273–1288. - PubMed
    1. Banasr M, Soumier A, Hery M, Mocaër E, Daszuta A. Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis. Biol Psychiatry. 2006;59:1087–1096. - PubMed
    1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. - PubMed
    1. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29:417–426. - PMC - PubMed

Publication types

MeSH terms

Substances